Literature DB >> 15486931

Pivotal role of nuclear factor kappaB signaling in anti-CD40-induced liver injury in mice.

Kiminori Kimura1, Masahito Nagaki, Shinji Takai, Shinichi Satake, Hisataka Moriwaki.   

Abstract

Nuclear factor kappaB (NF-kappaB) has a central role in coordinating the expression of a wide variety of genes that control immune responses and is also recognized as an antiapoptotic transcription factor. Here, we focused on the role of the NF-kappaB signaling pathway in the interaction between inflammatory cells and hepatocytes in liver inflammation. We found that pretreatment of mice with adenoviruses expressing a mutant form of the inhibitor kappaB superrepressor (Ad5IkappaB), a NF-kappaB inhibitor, reduced the migration of inflammatory cells and cytokine and chemokine expression in the liver 12 hours after a single intravenous injection of an anti-CD40 antibody (alphaCD40) compared with mice infected with control adenoviruses (Ad5LacZ). We also confirmed reductions in cytokine production by macrophages, T cells, and natural killer (NK) cells in the liver of Ad5IkappaB-treated mice by FACS analysis. However, alphaCD40 treatment in Ad5IkappaB-infected mice induced elevation of serum alanine aminotransferase at 24 hours, and the liver injury was associated with massive hepatocyte apoptosis. Furthermore, interferon gamma (IFN-gamma) production by NK cells and T cells was increased and stimulated tumor necrosis factor alpha (TNF-alpha) production by macrophages in the Ad5IkappaB-infected liver. Moreover, the liver injury was completely suppressed by the administration of anti-IFN-gamma and anti-TNF-alpha. These results suggest that inhibition of NF-kappaB activity suppressed alphaCD40-induced liver inflammation at an early phase, resulting in a reduction in cytokine and chemokine production, whereas it sensitized hepatocytes to TNF-alpha-induced apoptosis and exacerbated liver injury at the late phase. In conclusion, NF-kappaB exerts pivotal activities at inflammatory sites, and caution should be exercised in NF-kappaB-targeted therapy of liver disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486931     DOI: 10.1002/hep.20432

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Pathogenic role of B cells in anti-CD40-induced necroinflammatory liver disease.

Authors:  Kiminori Kimura; Hisataka Moriwaki; Masahito Nagaki; Masanao Saio; Yasunari Nakamoto; Makoto Naito; Kazuo Kuwata; Francis V Chisari
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

2.  Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis.

Authors:  Abdel-Majid Khatib; Patrick Auguste; Lucia Fallavollita; Ni Wang; Amir Samani; Maria Kontogiannea; Sarkis Meterissian; Pnina Brodt
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

3.  Role of CD44 in CTL-induced acute liver injury in hepatitis B virus transgenic mice.

Authors:  Kiminori Kimura; Masahito Nagaki; Masanao Saio; Hisataka Moriwaki; Kazuhiro Kakimi
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

4.  CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury.

Authors:  Xiuda Shen; Yue Wang; Feng Gao; Feng Ren; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Yuan Zhai
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

5.  Serum soluble CD40 is associated with liver injury in patients with chronic hepatitis B.

Authors:  Hong-Hui Shen; Bing-Ke Bai; Ya-Qing Wang; Guang-DE Zhou; Jun Hou; Yan Hu; Jing-Min Zhao; Bao-Sen Li; Hai-Li Huang; Pan-Yong Mao
Journal:  Exp Ther Med       Date:  2015-01-14       Impact factor: 2.447

6.  Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.

Authors:  Xinyue Qi; Fanlin Li; Yi Wu; Chen Cheng; Ping Han; Jieyi Wang; Xuanming Yang
Journal:  Nat Commun       Date:  2019-05-20       Impact factor: 14.919

7.  Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.

Authors:  Celia Jacoberger-Foissac; Stephen J Blake; Jing Liu; Elizabeth McDonald; Hannah Triscott; Kyohei Nakamura; Mark J Smyth; Michele Wl Teng
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.